Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013-2017

被引：14

作者：

Shimbashi, Reiko ^{[1
,2
]}

Suzuki, Motoi ^{[1
,2
]}

Chang, Bin ^{[1
]}

Watanabe, Hiroshi ^{[3
]}

Tanabe, Yoshinari ^{[4
]}

Kuronuma, Koji ^{[5
]}

Oshima, Kengo ^{[2
]}

Maruyama, Takaya ^{[6
]}

Takeda, Hiroaki ^{[7
]}

Kasahara, Kei ^{[8
]}

Fujita, Jiro ^{[9
]}

Nishi, Junichiro ^{[10
]}

Kubota, Tetsuya ^{[11
]}

Tanaka-Taya, Keiko ^{[1
]}

Matsui, Tamano ^{[1
]}

Sunagawa, Tomimasa ^{[1
]}

Oishi, Kazunori ^{[1
,12
]}

机构：

[1] Natl Inst Infect Dis, Tokyo, Japan

[2] Tohoku Univ, Grad Sch Med, Sendai, Miyagi, Japan

[3] Kurume Univ, Sch Med, Fukuoka, Japan

[4] Niigata Prefectural Shibata Hosp, Niigata, Japan

[5] Sapporo Med Univ, Sch Med, Sapporo, Hokkaido, Japan

[6] Natl Hosp Org Mie Natl Hosp, Tsu, Mie, Japan

[7] Yamagata Saisei Hosp, Yamagata, Japan

[8] Nara Med Univ, Nara, Japan

[9] Univ Ryukyus, Grad Sch Med, Nishihara, Okinawa, Japan

[10] Kagoshima Univ, Grad Sch Med & Dent Sci, Kagoshima, Japan

[11] Kochi Univ, Kochi Med Sch, Kochi, Japan

[12] Toyama Inst Hlth, Toyama, Japan

来源：

EMERGING INFECTIOUS DISEASES | 2020年 / 26卷 / 10期

关键词：

PNEUMONIAE SEROTYPE 12F; CONJUGATE VACCINE; POPULATION; IMPACT; OLDER; SPAIN;

D O I：

10.3201/eid2610.191531

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The decline in the proportion of pneumococcal conjugate vaccine (PCV)-covered serotypes among adult invasive pneumococcal disease (IPD) patients might change the overall effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) because its effectiveness differs according to serotype. Using the indirect cohort method, we calculated the effectiveness of PPSV23 against IPD among adults in Japan to assess the impact of the national pediatric PCV program. Clinical and epidemiologic information and pneumococcal isolates were collected from IPD patients >= 20 years of age through enhanced IPD surveillance during April 2013-December 2017. Adjusted effectiveness against PPSV23-serotype IPD was 42.2%. Despite a substantial decline in the proportion of 13-valent PCV serotypes during the study period (45% to 31%), the change in effectiveness for PPSV23-serotype IPD was limited (47.1% to 39.3%) and only marginal in the elderly population (39.9% to 39.4%). The pediatric PCV program had limited impact on PPSV23 effectiveness against IPD in adults.

引用

页码：2378 / 2386

页数：9

共 50 条

[31] Relative effectiveness of revaccination with 23-valent pneumococcal polysaccharide vaccine in preventing invasive pneumococcal disease in adult Aboriginal and Torres Strait Islander people, Australia
Takashima, Mari
Lambert, Stephen B.
Paynter, Stuart
Ware, Robert S.
VACCINE, 2019, 37 (12) : 1638 - 1641
[32] Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations
Wang, Yang
Li, Jingxin
Wang, Yuxiao
Gu, Wei
Zhu, Fengcai
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (04) : 1003 - 1012
[33] Recommendations for the use of the 23-valent polysaccharide pneumococcal vaccine in adults: A Belgian consensus report
Peetermans, WE
Van de Vyver, N
Van Laethem, Y
Van Damme, P
Thiry, N
Trefois, P
Geerts, P
Schetgen, M
Peleman, R
Swennen, B
Verhaegen, J
ACTA CLINICA BELGICA, 2005, 60 (06) : 329 - 337
[34] Clinical presentations and serotypes causing invasive pneumococcal disease in adults vaccinated with the 23-valent polysaccharide pneumococcal vaccine (PPV23) in Spain. The ODIN study (2010-2013)
Torres, Antoni
Bouza, Emilio
Pallares, Roman
Molinos, Luis
Salavert, Miguel
Llinares, Pedro
De la Cruz, Jose Luis
Alfageme, Inmaculada
Rajas, Olga
Fenoll, Asuncion
Linares, Josefina
Mendez, Cristina
EUROPEAN RESPIRATORY JOURNAL, 2014, 44
[35] Clinical presentations and serotypes causing invasive pneumococcal disease in adults vaccinated with the 23-valent polysaccharide pneumococcal vaccine (PPV23) in Spain. The ODIN study (2010-2013)
Torres, Antoni
Bouza, Emilio
Pallares, Roman
Molinos, Luis
Salavert, Miguel
Llinares, Pedro
De la Cruz, Jose Luis
Alfageme, Inmaculada
Rajas, Olga
Fenoll, Asuncion
Linares, Josefina
Mendez, Cristina
EUROPEAN RESPIRATORY JOURNAL, 2014, 44
[36] Revaccination of adults with spinal cord injury using the 23-valent pneumococcal polysaccharide vaccine
Waites, Ken B.
Canupp, Kay C.
Chen, Yu-ying
DeVivo, Michael J.
Nahm, Moon H.
JOURNAL OF SPINAL CORD MEDICINE, 2008, 31 (01): : 53 - 59
[37] Priming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine
Rose, MA
Schubert, R
Strnad, N
Zielen, S
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2005, 12 (10) : 1216 - 1222
[38] Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children
Sigurdardottir, Sigurveig Th.
Center, Kimberly J.
Davidsdottir, Katrin
Arason, Vilhjalmur A.
Hjalmarsson, Bjorn
Elisdottir, Ragnheidur
Ingolfsdottir, Gunnhildur
Northington, Robert
Scott, Daniel A.
Jonsdottir, Ingileif
VACCINE, 2014, 32 (03) : 417 - 424
[39] The Efficacy of 23-Valent Pneumococcal Polysaccharide Vaccine in Preventing Pneumonia and Invasive Pneumococcal Disease in the Elderly Aged 75 Years and Older in Taiwan
Hsieh, Meng-Jer
Tsai, Ying-Huang
Chang, Chee-Jen
Wen, Yu-Wen
Hu, Han-Chung
Chao, Yen-Nan
Huang, Yhu-Chering
Yang, Cheng-Ta
Huang, Chung-Chi
CHEST, 2013, 144 (04)
[40] Immunogenicity of A 23-Valent Pneumococcal Polysaccharide Vaccine Among Mexican Children
Elva Espinosa-Padilla, Sara
Murata, Chiharu
Estrada-Parra, Sergio
Santos-Argumedo, Leopoldo
Mascarenas, Cesar
Franco-Paredes, Carlos
Javier Espinosa-Rosales, Francisco
ARCHIVES OF MEDICAL RESEARCH, 2012, 43 (05) : 402 - 405

← 1 2 3 4 5 →